EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Petra Langerbeins iD, Sandra Robrecht, Pascal Nieper iD, Paula Cramer iD, Moritz Fürstenau iD, Othman Al-Sawaf iD, Florian Simon iD, Anna-Maria Fink iD, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch iD, Christof Schneider und 24 weitere

Journal of Clinical Oncology · 2025-02 · 43 (4) · 392-402

DOI: 10.1200/jco.24.00975 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Petra Langerbeins und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Faculty of Medicine and Un…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Pyrimidines, Pyrazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. METHODS The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group. The final analysis included event-free survival, progression-free survival, time to next treatment, overall survival, and safety assessments. RESULTS Ibrutinib significantly delayed progression to symptomatic disease ( P < .001; hazard ratio, 0.276 [95% CI, 0.188 to 0.407]), but no survival benefit was observed with 26 death cases ( P = .562) at a median observation time of 69.3 months. Five-year survival rates were excellent: 93.3% (95% CI, 89.3 to 97.3) in the ibrutinib group, 93.6% (95% CI, 89.5 to 97.7) in the placebo group, and 97.9% (95% CI, 95.6 to 100) in the watch-and-wait cohort. Estimated 10-year survival rates from diagnosis were 86.5% (95% CI, 78.7 to 94.3, placebo), 89.8% (95% CI, 83.3 to 96.3, ibrutinib), and 95.3% (95% CI, 91.1 to 99.4, watch and wait). In the ibrutinib group, one of 12 deaths was CLL-associated, compared with four of 14 fatal cases of CLL progression or Richter transformation in the placebo group. Adverse and serious adverse events occurred in 99.4% and 60% of both treatment groups, respectively. The safety profile indicated increased cardiovascular toxicity in the ibrutinib group. CONCLUSION Ibrutinib treatment in early-stage CLL delayed disease progression compared with placebo. However, with the given observation time and few deaths, no survival benefit was demonstrated. In the era of targeted therapies, watch and wait remains the standard of care irrespective of risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellPyrimidinesPyrazolesProtein Kinase InhibitorsHumansPiperidinesAdenineDouble-Blind MethodMaleFemaleMiddle AgedAgedAged, 80 and overAdultProgression-Free SurvivalNeoplasm StagingWatchful WaitingDisease Progression

Substanzen

PiperidinesAdenineibrutinibPyrimidinesPyrazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • ÜBAG MVZ Dr Vehling-Kaiser GmbH, Landshut, Germany.
  • Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Study Centrum Unter Ems, Practice for Oncology and Hematology, Leer, Germany.
  • Practice for Oncology and Hematology, Erlangen, Germany.
  • Practice for Oncology and Hematology, Würzburg, Germany.

ORCID-Profile: Petra Langerbeins, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Eugen Tausch, Lothar Müller, Holger Hebart, Michael Hallek

Zitieren

APA

Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al-Sawaf, O., Simon, F., Fink, A. M., Kreuzer, K. A., Vehling-Kaiser, U., Tausch, E., Schneider, C., Müller, L., Eckart, M. J., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., …, & Hallek, M. (2025). Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. Journal of Clinical Oncology, 43(4), 392-402. https://doi.org/10.1200/jco.24.00975

Vancouver

Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, et al. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. Journal of Clinical Oncology. 2025;43(4):392-402. doi:10.1200/jco.24.00975

BibTeX
@article{Langerbeins2025,
  author = {Langerbeins, Petra and Robrecht, Sandra and Nieper, Pascal and Cramer, Paula and Fürstenau, Moritz and Al-Sawaf, Othman and Simon, Florian and Fink, Anna-Maria and Kreuzer, Karl-Anton and Vehling-Kaiser, Ursula and Tausch, Eugen and Schneider, Christof and Müller, Lothar and Eckart, Michael Josef and Schlag, Rudolf and Freier, Werner and Gaska, Tobias and Balser, Christina and Reiser, Marcel and Stauch, Martina and Zahn, Mark-Oliver and Dörfel, Steffen and Staib, Peter and Behlendorf, Timo and Hensel, Manfred and Hebart, Holger and Klaproth, Holger and Block, Andreas and Liersch, Rüdiger and Hauch, Ulrich and Heinrich, Bernhard and Wendtner, Clemens-Martin and Fischer, Kirsten and Stilgenbauer, Stephan and Eichhorst, Barbara and Hallek, Michael},
  title = {Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {392--402},
  doi = {10.1200/jco.24.00975}
}
Kostenlos starten →